GlassScriptPhysician profile
Erol R Atamer
NPI 1003812322
$2,916.14
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,946 · 2020: $842 · 2021: $128.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $550.81 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $440.66 | 2019-2020 | |
| Novo Nordisk INC | $348.12 | 2019-2021 | |
| Pfizer INC. | $286.88 | 2019-2020 | |
| Amarin Pharma, INC. | $216.34 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $120.02 | 2019 | |
| Glaxosmithkline, LLC. | $119.98 | 2019 | |
| Daiichi Sankyo INC. | $118.30 | 2019-2020 | |
| Coala Life INC | $110.63 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $109.25 | 2019-2020 | |
| Lilly USA, LLC | $63.48 | 2019-2020 | |
| Allergan, INC. | $54.30 | 2019-2020 | |
| Astellas Pharma US INC | $50.86 | 2019-2021 | |
| Tosoh Bioscience, INC. | $50.00 | 2019 | |
| Sanofi Pasteur INC. | $37.29 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.36 | 2019 | |
| Bioventus LLC | $24.58 | 2020 | |
| Janssen Pharmaceuticals, INC | $21.82 | 2019 | |
| Avanir Pharmaceuticals, INC. | $21.44 | 2019 | |
| Vivus LLC | $21.07 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.61 | 2019 | |
| Abbott Laboratories | $19.25 | 2020 | |
| Vertiflex, INC. | $19.19 | 2019 | |
| Seqirus USA INC | $18.12 | 2019 | |
| Eisai INC. | $17.03 | 2020 | |
| Scilex Pharmaceuticals INC. | $15.45 | 2019 | |
| Genentech USA, INC. | $15.30 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erol Atamer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.